Premium
Effects of prolonged administration of two new α‐glucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin‐dependent diabetes mellitus
Author(s) -
DIMITRIADIS G.,
HATZIAGELAKI E.,
LADAS S.,
LINOS ATHENA,
HILLEBRAND INGRID,
RAPTIS S.
Publication year - 1988
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1988.tb01162.x
Subject(s) - postprandial , medicine , insulin , endocrinology , crossover study , placebo , diabetes mellitus , carbohydrate , alternative medicine , pathology
. Alpha‐glucosidase inhibitors delay carbohydrate absorption. In order to study the effects of two new α‐glucosidase inhibitors with long (BAYo1248) and short (BAYm1099) duration of action on glycaemic control, seventeen insulin‐dependent diabetics were connected to the Biostator® for 24 h and postprandial hyperglycaemia, insulin requirements and breath H 2 concentrations were assessed under three conditions: (a) before administration of any α‐glucosidase inhibitor (control experiments), (b) after administration of BAYo1248 (40 mg before breakfast, nine patients) or BAYm1099 (100 mg before breakfast and dinner, eight patients) for 1 month, (c) after 1‐month administration of placebo (double‐blind crossover study). All patients were on standard diets (30 kcal kg ‐1 , 45% carbohydrate, 35% fat, 20% protein). BAYo1248 reduced postprandial hyperglycaemia and insulin requirements (vs. values in control and placebo experiments) after breakfast (124 ± 8 vs. 159 ± 8 and 158 ± 8 mg dl ‐1 , 16 ± 2 vs. 24 ± 4 and 23 ± 3 units, P <0·01) and lunch (138 ± 7 vs. 155 ± 11 and 162 ± 13 mg dl ‐1 , 19 ± 3 vs. 24 ± 3 and 23 ± 3 units, P <0·01) whereas BAYm1099 reduced postprandial hyperglycaemia and insulin requirements after breakfast (127 ± 4 vs. 167 ± 12 and 159 ± 6 mg dl ‐1 , 15 ± 3 vs. 24 ± 4 and 21 ± 3 units, P <0·02) and dinner (128 ± 4 vs. 169 ± 7 and 157 ± 10 mg dl ‐1 , 19 ± 2 vs. 28 ± 3 and 25 ± 2 units, P <0·01). Postprandial breath H 2 concentrations were mildly increased when BAYo1248 and BAYm1099 were administered, compared with control and placebo experiments (BAYo1248:37 ± 5 vs. 9 ± 2 and 9 ± 4 ppm, BAYm1099 37 ± 10 vs. 9 ± 3 and 13 ± 3 ppm, P <0·05). In conclusion, improvement of glycaemic control, reduction of insulin requirements and virtual absence of malabsorption may make these agents useful adjuncts to insulin in the treatment of diabetes mellitus.